VISCHER advised Anaveon on the deal.Anaveon AG, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110m Series B financing led by incoming investor Forbion,…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Federica Tiefenthaler
…
This content is for Standard 1 Year members only. LoginJoin Now